Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3Prostatic Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Nivolumab 37pembrolizumab 26cabozantinib 26Specimen Handling 23Magnetic Resonance Spectroscopy 21Ipilimumab 19lenvatinib 13belzutifan 13Axitinib 13CTLA-4 Antigen 10Sunitinib 9Radiosurgery 8Biopsy 8atezolizumab 7fludarabine 4avelumab 4aldesleukin 4Immunoglobulin G 4Disulfides 4zimberelimab 3toripalimab 3tivozanib 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3Surveys and Questionnaires 3Nephrectomy 3Everolimus 3Cyclophosphamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × tivozanib × 90 days × Clear all
NCT06661720 2026-06-02

STRIKE

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
1,040 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
48 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡